肿瘤细胞治疗研究
英文原题：Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.
在过去几年中，双靶点嵌合抗原受体（CAR）T细胞疗法已被用于血液系统恶性肿瘤的治疗，以减少治疗失败，特别是在抗原逃逸的情况下。
在过去几年中，双靶点嵌合抗原受体（CAR）T细胞疗法已被用于血液系统恶性肿瘤的治疗，以减少治疗失败，特别是在抗原逃逸的情况下。最广泛使用的方法包括CD19/CD20、CD20/CD22和BCMA/CD19 CAR T细胞。其他免疫细胞，包括自然杀伤T细胞和恒定自然杀伤T细胞，表现出固有的抗肿瘤活性和较低的毒性。本综述总结了2023年美国血液学会（ASH）年会上关于双靶点CAR T细胞免疫治疗血液系统恶性肿瘤的若干近期临床试验报告和临床前研究。
Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of antigen escape. The most widely used approaches include CD19/CD20, CD20/CD22, and BCMA/CD19 CAR T-cells. Alternative immune cells, including natural killer T cells and invariant natural killer T cells, exhibit innate anti-tumor activity and reduced toxicity. This review summarizes several recent clinical trial reports and preclinical studies from the 2023 American Society of Hematology (ASH) annual meeting on dual-targeted CAR T-cell immunotherapy for hematological malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
